Cephalexin News
Advancis Pharmaceutical Announces Launch of Keflex 750mg Capsules
Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced the commercial launch of Keflex 750mg capsules. The new...
Advancis Pharmaceutical Corporation launches Keflex(R) powder for oral suspension in the United States.
Advancis Pharmaceutical Corporation a pharmaceutical company focused on developing and commercializing novel anti-infective products, announced today that it has launched Keflex® Powder for Oral Suspension (Cephalexin, USP). The...
Skin and Soft-Tissue Infections.
We encounter soft-tissue infections commonly and, fortunately, most get better with antibiotics. A hundred years ago, however, soft-tissue infections were the cause of sepsis and death. We all recognize that antibiotic resistance...
Advancis Pharmaceutical Receives FDA approval letter for new strengths of Keflex
Advancis Pharmaceutical Corporation , a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that the U.S. Food and Drug Administration (FDA) has issued an Approval...
Advancis Pharmaceutical Provides Update on Additional Keflex Products.
Advancis Pharmaceutical Corporation (NASDAQ: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that the U.S. Food and Drug Administration (FDA) has informed...